Is MLYS a Buy? What to Consider in 2026
Short answer
The bull case for Mineralys Therapeutics (MLYS) rests on Lorundrostat FDA decision: The single largest driver is the FDA review of lorundrostat, with a PDUFA target date of December 22, 2026. Product revenue (TTM) is ~$0 (pre-commercial). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Whether MLYS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026, positioning Mineralys as it transitions toward a potential pre-commercial stage. The investment picture is that of a classic binary biotech. As a pre-revenue company, Mineralys reported a net loss (roughly $39.3 million in Q1 2026) funded by a large cash position of around $646 million as of March 31, 2026, which management expects to fund operations into 2028. The stock, valued near $2.3 billion, prices in a meaningful probability of approval and commercial success for lorundrostat in a very large hypertension market. The flip side is concentration risk: a negative FDA decision, a competitive setback, or a disappointing launch would weigh heavily because there is no diversified pipeline or product revenue to cushion it.
What's the case for buying MLYS?
1. Lorundrostat FDA decision
The single largest driver is the FDA review of lorundrostat, with a PDUFA target date of December 22, 2026. An approval would move Mineralys from clinical-stage to a commercial-stage company with a first-in-class-tier aldosterone synthase inhibitor. The decision is the defining catalyst for the stock over the coming year.
2. Large uncontrolled-hypertension market
Uncontrolled and resistant hypertension affects a very large patient population that remains poorly served by existing generic therapies. Lorundrostat targets aldosterone, a hormone implicated in blood pressure that current standard regimens do not directly address. If approved and adopted, even modest penetration of this market could support substantial revenue.
3. Pipeline expansion into CKD and OSA
Beyond core hypertension, Mineralys is studying lorundrostat in chronic kidney disease and obstructive sleep apnea, conditions where aldosterone dysregulation plays a role. Positive data in these adjacent indications could broaden the drug's addressable market and lengthen its commercial runway well beyond an initial hypertension label.
4. Balance sheet and launch readiness
With roughly $646 million in cash as of March 2026 and runway guided into 2028, Mineralys has capital to fund a potential launch and continued trials without immediate financing pressure. The company has also raised additional equity in 2026, adding cushion but modestly diluting existing holders.
What are the risks to MLYS?
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash and has raised equity, creating dilution risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to trial readouts and regulatory news.
How is MLYS valued? (as of JUNE 2026)
Snapshot for MLYS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Product revenue (TTM): ~$0 (pre-commercial)
- Cash & investments: ~$646M (Mar 2026)
- Q1 2026 net loss: ~$39M
- Q1 2026 R&D expense: ~$24M
- Market cap: ~$2.3B
- Shares outstanding: ~88M (post June 2026 offering)
Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $2.3 billion market value reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. Cash of about $646 million as of March 2026, with runway guided into 2028, is the key financial cushion ahead of the December 2026 FDA decision.
How do you decide if MLYS is a buy?
Rather than asking whether MLYS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MLYS indirectly through an index or sector ETF before adding more.
For the full picture, see the MLYS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MLYS against your real portfolio and see your actual exposure before deciding.
The bottom line on MLYS
The bottom line: Mineralys Therapeutics's story right now is Lorundrostat FDA decision, with product revenue (ttm) at ~$0 (pre-commercial). If you believe that narrative continues, the call is about sizing MLYS sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around MLYS with Walnut
Use Mineralys Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MLYS a good stock to buy right now?
+
The case for Mineralys Therapeutics right now is Lorundrostat FDA decision, with product revenue (ttm) at ~$0 (pre-commercial). If you believe that thesis holds, MLYS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Mineralys Therapeutics do?
+
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by
What are the main risks of MLYS?
+
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash and has raised equity, creating dilution risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to trial readouts and regulatory news.
What does Mineralys Therapeutics (MLYS) do?
+
Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension, with additional research in chronic kidney disease and obstructive sleep apnea. It is based in Radnor, Pennsylvania.
Does MLYS have any approved products or revenue?
+
No. As of mid-2026 Mineralys has no approved products and no product revenue. It is pre-commercial, funding operations from its cash balance while its lead drug lorundrostat is under FDA review.
What is the FDA decision date for lorundrostat?
+
The FDA accepted the lorundrostat New Drug Application and set a PDUFA target action date of December 22, 2026. That decision is the single most important near-term event for the company and the stock.
How much cash does Mineralys have?
+
Mineralys reported roughly $646 million in cash and investments as of March 31, 2026, and management has guided that this funds operations into 2028. The company also raised additional equity in June 2026.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MLYS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.